Article Versions Notes

Li H-K, Wu T-S, Kuo Y-C, Hsiao C-W, Yang H-P, Lee C-Y, Leng P-J, Chiang Y-J, Cheng Z-F, Yang S-H, et al. A Novel Allogeneic Rituximab-Conjugated Gamma Delta T Cell Therapy for the Treatment of Relapsed/Refractory B-Cell Lymphoma. Cancers. 2023; 15(19):4844. https://doi.org/10.3390/cancers15194844

Li, Hao-Kang, Tai-Sheng Wu, Yi-Chiu Kuo, Ching-Wen Hsiao, Hsiu-Ping Yang, Chia-Yun Lee, Pei-Ju Leng, Yun-Jung Chiang, Zih-Fei Cheng, Sen-Han Yang, and et al. 2023. "A Novel Allogeneic Rituximab-Conjugated Gamma Delta T Cell Therapy for the Treatment of Relapsed/Refractory B-Cell Lymphoma" Cancers 15, no. 19: 4844. https://doi.org/10.3390/cancers15194844

Li, H.-K., Wu, T.-S., Kuo, Y.-C., Hsiao, C.-W., Yang, H.-P., Lee, C.-Y., Leng, P.-J., Chiang, Y.-J., Cheng, Z.-F., Yang, S.-H., Lin, Y.-L., Chen, L.-Y., Chen, C.-S., Chen, Y.-J., Hsiao, S.-C., & Tang, S.-W. (2023). A Novel Allogeneic Rituximab-Conjugated Gamma Delta T Cell Therapy for the Treatment of Relapsed/Refractory B-Cell Lymphoma. Cancers, 15(19), 4844. https://doi.org/10.3390/cancers15194844